<code id='F314460B95'></code><style id='F314460B95'></style>
    • <acronym id='F314460B95'></acronym>
      <center id='F314460B95'><center id='F314460B95'><tfoot id='F314460B95'></tfoot></center><abbr id='F314460B95'><dir id='F314460B95'><tfoot id='F314460B95'></tfoot><noframes id='F314460B95'>

    • <optgroup id='F314460B95'><strike id='F314460B95'><sup id='F314460B95'></sup></strike><code id='F314460B95'></code></optgroup>
        1. <b id='F314460B95'><label id='F314460B95'><select id='F314460B95'><dt id='F314460B95'><span id='F314460B95'></span></dt></select></label></b><u id='F314460B95'></u>
          <i id='F314460B95'><strike id='F314460B95'><tt id='F314460B95'><pre id='F314460B95'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:74
          Illustration of a hospital being handed from a doctor to a business person – politics and policy coverage from STAT
          New guidelines from federal antitrust enforcers would have big implications on health care deals. Adobe

          Health care companies trying to merge can expect tougher policing from the top federal antitrust agencies, according to a set of new draft guidelines released Wednesday.

          The Department of Justice and Federal Trade Commission laid out 13 proposed guidelines detailing how they will judge whether proposed mergers and acquisitions are anticompetitive and should be challenged.

          advertisement

          The rules would apply broadly across the economy, but they have strong implications for the health care industry, where sizable deals among hospitals, physician practices, private equity firms, health insurers, pharmacy benefit managers, pharmaceutical companies, medical device firms, and numerous other entities occur almost weekly. Research has shown that health care’s highly concentrated markets are a major reason why prices and spending have soared for patients and taxpayers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          What STAT readers think about the FDA and patient advocacy
          What STAT readers think about the FDA and patient advocacy

          MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          CRISPR gene editing developments we’re watching in 2024

          ChristineKao/STATLifeintheCRISPRlanetendstomoveatlightningspeed.Thisyearsawthefirst-everapprovalofam